# Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

> **NCT05652920** · PHASE1,PHASE2 · RECRUITING · sponsor: **OriCell Therapeutics Co., Ltd.** · enrollment: 105 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Ori-C101

## Key facts

- **NCT ID:** NCT05652920
- **Lead sponsor:** OriCell Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05652920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05652920, "Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05652920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*